α-[¹¹C]-methyl-L-tryptophan PET for tracer localization of epileptogenic brain regions: clinical studies
- PMID: 22003906
- PMCID: PMC3226729
- DOI: 10.2217/bmm.11.68
α-[¹¹C]-methyl-L-tryptophan PET for tracer localization of epileptogenic brain regions: clinical studies
Abstract
Of several molecular probes used in PET, only α-[(11)C]-methyl-L-tryptophan (AMT) is able to pinpoint the epileptic focus itself in the interictal state, by revealing a focus of increased AMT uptake, even when an MRI or glucose metabolism PET demonstrates normal findings. AMT PET appears to be particularly useful in patients with tuberous sclerosis complex and in patients with cortical developmental malformations. Although the sensitivity of AMT PET in finding the epileptic focus is about 70%, its specificity is almost 100%, indicating that if AMT PET identifies an area of increased uptake, it likely represents the epileptic focus which needs to be resected for better surgical outcome. In nontuberous sclerosis complex patients with cortical dysplasia, increased AMT uptake is usually associated with cortical dysplasia type IIB and a very good surgical outcome. Previously, no imaging modality has been able to predict the exact pathology subtype or differentiate between epileptogenic and nonepileptogenic lesions interictally. The neuropathological similarities between tubers and type IIB cortical dysplasia suggest a common mechanism of epilepsy, for which AMT PET is a biomarker. Due to the limited access to AMT PET, as presently it is labeled with (11)C, which has a half-life of only 20 min and therefore has to be synthesized on site using a cyclotron, most of the AMT experience has originated primarily from only two centers. Therefore, there is a need for more clinical studies from other centers and this can be greatly facilitated if AMT can be labeled with (18)F, a PET radionuclide widely available with a half-life of 110 min.
Conflict of interest statement
The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
No writing assistance was utilized in the production of this manuscript.
Figures




Similar articles
-
α-methyl-L-tryptophan: mechanisms for tracer localization of epileptogenic brain regions.Biomark Med. 2011 Oct;5(5):567-75. doi: 10.2217/bmm.11.73. Biomark Med. 2011. PMID: 22003905 Free PMC article. Review.
-
Epilepsy surgery outcome in children with tuberous sclerosis complex evaluated with alpha-[11C]methyl-L-tryptophan positron emission tomography (PET).J Child Neurol. 2005 May;20(5):429-38. doi: 10.1177/08830738050200050701. J Child Neurol. 2005. PMID: 15971355
-
Imaging epileptogenic tubers in children with tuberous sclerosis complex using alpha-[11C]methyl-L-tryptophan positron emission tomography.Ann Neurol. 1998 Dec;44(6):858-66. doi: 10.1002/ana.410440603. Ann Neurol. 1998. PMID: 9851429
-
Alpha-methyl-L-tryptophan PET detects epileptogenic cortex in children with intractable epilepsy.Neurology. 2003 Mar 25;60(6):960-8. doi: 10.1212/01.wnl.0000049468.05050.f2. Neurology. 2003. PMID: 12654960
-
Surgical treatment of West syndrome.Brain Dev. 2001 Nov;23(7):668-76. doi: 10.1016/s0387-7604(01)00305-9. Brain Dev. 2001. PMID: 11701275 Review.
Cited by
-
The challenge and promise of anti-epileptic therapy development in animal models.Lancet Neurol. 2014 Sep;13(9):949-60. doi: 10.1016/S1474-4422(14)70076-6. Epub 2014 Aug 10. Lancet Neurol. 2014. PMID: 25127174 Free PMC article. Review.
-
α-Methyl-l-tryptophan as a weight-loss agent in multiple models of obesity in mice.Biochem J. 2021 Apr 16;478(7):1347-1358. doi: 10.1042/BCJ20210100. Biochem J. 2021. PMID: 33720280 Free PMC article.
-
α-methyl-L-tryptophan: mechanisms for tracer localization of epileptogenic brain regions.Biomark Med. 2011 Oct;5(5):567-75. doi: 10.2217/bmm.11.73. Biomark Med. 2011. PMID: 22003905 Free PMC article. Review.
-
The treatment value of IL-1β monoclonal antibody under the targeting location of alpha-methyl-L-tryptophan and superparamagnetic iron oxide nanoparticles in an acute temporal lobe epilepsy model.J Transl Med. 2018 Dec 4;16(1):337. doi: 10.1186/s12967-018-1712-3. J Transl Med. 2018. PMID: 30514296 Free PMC article.
-
Why is there still doubt to cut it out?Epilepsy Curr. 2013 Sep;13(5):198-204. doi: 10.5698/1535-7597-13.5.198. Epilepsy Curr. 2013. PMID: 24348103 Free PMC article.
References
-
- Arroyo S. [Evaluation of drug-resistant epilepsy] [Article in Spanish] Rev. Neurol. 2000;30(9):881–886. - PubMed
-
- Guerrini R, Sicca F, Parmeggiani L. Epilepsy and malformations of the cerebral cortex. Epileptic Disord. 2003;5 Suppl. 2:S9–S26. - PubMed
-
- Kwan P, Brodie MJ. Early identification of refractory epilepsy. N. Engl. J. Med. 2000;342(5):314–319. - PubMed
-
- Obeid M, Wyllie E, Rahi AC, Mikati MA. Approach to pediatric epilepsy surgery: state of the art, Part I: General principles and presurgical workup. Eur. J. Paediatr. Neurol. 2009;13(2):102–114. - PubMed
-
- Juhász C, Chugani DC, Muzik O, et al. α-methyl-l-tryptophan PET detects epileptogenic cortex in children with intractable epilepsy. Neurology. 2003;60(6):960–968. - PubMed